Humanigen Inc (HGEN) Major Shareholder Buys $2,882,580.21 in Stock
Humanigen Inc (OTCMKTS:HGEN) major shareholder Dale Chappell acquired 32,028,669 shares of the company’s stock in a transaction on Tuesday, February 27th. The shares were purchased at an average cost of $0.09 per share, with a total value of $2,882,580.21. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Shares of Humanigen Inc (OTCMKTS:HGEN) opened at $0.75 on Friday. Humanigen Inc has a twelve month low of $0.13 and a twelve month high of $3.00. The company has a debt-to-equity ratio of -0.06, a current ratio of 0.10 and a quick ratio of 0.10.
COPYRIGHT VIOLATION NOTICE: This report was posted by Daily Political and is the property of of Daily Political. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://www.dailypolitical.com/2018/03/03/humanigen-inc-hgen-major-shareholder-buys-2882580-21-in-stock.html.
Humanigen, Inc, formerly KaloBios Pharmaceuticals, Inc, is a biopharmaceutical company. The Company focuses on developing medicines for patients with neglected and rare diseases, with an ancillary focus on pediatric conditions. The Company’s product candidate is benznidazole for the treatment of Chagas disease, a parasitic illness that can lead to long-term heart, intestinal and neurological problems.
Receive News & Ratings for Humanigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humanigen and related companies with MarketBeat.com's FREE daily email newsletter.